Log In
Print
BCIQ
Print
Print this Print this
 

Nalbuphine ER (T111)

  Manage Alerts
Collapse Summary General Information
Company Endo Health Solutions Inc.
DescriptionExtended-release oral formulation of nalbuphine, a mu opioid receptor (OPRM1; MOR) antagonist and kappa opioid receptor agonist
Molecular Target Mu opioid receptor (OPRM1) (MOR) ; Kappa opioid receptor (OPRK1) (KOR)
Mechanism of Action 
Latest Stage of DevelopmentPhase I
IndicationItch
Partner

Trevi Therapeutics Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today